Irisin Hormone Levels in Endometrial Hyperplasia
The Relation Between Serum Irisin Hormone Level and Endometrial Hyperplasia
1 other identifier
observational
80
1 country
1
Brief Summary
The purpose of the study is to determine serum irisin hormone levels an its relation between endometrial hyperplasia
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2016
CompletedFirst Submitted
Initial submission to the registry
September 13, 2016
CompletedFirst Posted
Study publicly available on registry
September 16, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2017
CompletedSeptember 16, 2016
September 1, 2016
5 months
September 13, 2016
September 13, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum irisin hormone levels in endometrial hyperplasia
6 months
Study Arms (2)
Endometrial Hyperplasia
The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
Control group
The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms
Eligibility Criteria
The study consisted of two groups. The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically, and the controls were healthy women admitted to the clinic just for annual examination without any complain and symptoms.
You may qualify if:
- between 35-50 years of age
- İn endometrial hyperplasia group; patients who were diagnosed endometrial hyperplasia histopathologically
You may not qualify if:
- Pregnancy
- Liver function disorders
- Cardiovascular disease
- Metabolic disease
- Diabetes
- Chronic kidney disease
- Central nerves system disease
- Immunosuppressive drug use
- Another known malignancy
- Excessive exercises in among one month
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kayseri Training and Research Hospital
Kayseri, 38000, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Erdem SAHİN
Kayseri Training and Research Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 13, 2016
First Posted
September 16, 2016
Study Start
August 1, 2016
Primary Completion
January 1, 2017
Study Completion
February 1, 2017
Last Updated
September 16, 2016
Record last verified: 2016-09